Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …

Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …

Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Introduction: Epidermal growth factor receptor (EGFR) mutations are well-described drivers
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …

Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …